Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial
Abstract: Background: There are no effective treatments for multiple system atrophy (MSA). Objective: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA. Methods: This was a double-blind, parallel-group, placebo-controlled, randomized trial in patients with "probable" MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA-Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score. Results: A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (-2.13 units [95% confidence interval, CI, -4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12-week in UMSARS Part II (exploratory outcome: -1.41 units [95% CI, -2.84; 0.03]; p = 0.05) and in MSA-QoL emotional/social dimension (secondary outcome: -6.99 units [95% CI, -13.40; -0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo). Conclusion: The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation.
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Artículo biblioteca |
Language: | eng |
Published: |
Wiley
2021
|
Subjects: | NEUROBIOLOGIA, ENFERMEDADES NEURODEGENERATIVAS, ENFERMEDAD DE PARKINSON, ENSAYO CLINICO, TRATAMIENTO MEDICO, ATROFIA MULTISISTÉMICA, |
Online Access: | https://repositorio.uca.edu.ar/handle/123456789/11645 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:ucacris:123456789-11645 |
---|---|
record_format |
koha |
spelling |
oai:ucacris:123456789-116452024-03-21T11:57:44Z Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial Rascol, Olivier Cochen De Cock, Valérie Pavy-Le Traon, Anne Foubert Samier, Alexandra Thalamas, Claire Sommet, Agnès Rousseau, Vanessa Pérez Lloret, Santiago Fabbri, Margherita Azulay, Jean Philippe Corvol, Jean-Christophe Couratier, Philippe Damier, Philippe Defebvre, Luc Durif, Franck Geny, Christian Houeto, Jean-Luc Remy, Philippe Tranchant, Christine Verin, Marc Tison, François Meissner, Wassilios G. NEUROBIOLOGIA ENFERMEDADES NEURODEGENERATIVAS ENFERMEDAD DE PARKINSON ENSAYO CLINICO TRATAMIENTO MEDICO ATROFIA MULTISISTÉMICA Abstract: Background: There are no effective treatments for multiple system atrophy (MSA). Objective: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA. Methods: This was a double-blind, parallel-group, placebo-controlled, randomized trial in patients with "probable" MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA-Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score. Results: A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (-2.13 units [95% confidence interval, CI, -4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12-week in UMSARS Part II (exploratory outcome: -1.41 units [95% CI, -2.84; 0.03]; p = 0.05) and in MSA-QoL emotional/social dimension (secondary outcome: -6.99 units [95% CI, -13.40; -0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo). Conclusion: The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation. 2021-06-17T17:54:44Z 2021-06-17T17:54:44Z 2021 Artículo Rascol, O., et al. Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial [en línea]. Postprint del artículo publicado en: Movement Disorders. 2021. doi: 10.1002/mds.28569. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11645 1531-8257 https://repositorio.uca.edu.ar/handle/123456789/11645 10.1002/mds.28569 eng Acceso abierto. 12 meses de embargo http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Wiley Postprint del artículo publicado en: Movement Disorders. 2021 |
institution |
UCA |
collection |
DSpace |
country |
Argentina |
countrycode |
AR |
component |
Bibliográfico |
access |
En linea |
databasecode |
dig-uca |
tag |
biblioteca |
region |
America del Sur |
libraryname |
Sistema de bibliotecas de la UCA |
language |
eng |
topic |
NEUROBIOLOGIA ENFERMEDADES NEURODEGENERATIVAS ENFERMEDAD DE PARKINSON ENSAYO CLINICO TRATAMIENTO MEDICO ATROFIA MULTISISTÉMICA NEUROBIOLOGIA ENFERMEDADES NEURODEGENERATIVAS ENFERMEDAD DE PARKINSON ENSAYO CLINICO TRATAMIENTO MEDICO ATROFIA MULTISISTÉMICA |
spellingShingle |
NEUROBIOLOGIA ENFERMEDADES NEURODEGENERATIVAS ENFERMEDAD DE PARKINSON ENSAYO CLINICO TRATAMIENTO MEDICO ATROFIA MULTISISTÉMICA NEUROBIOLOGIA ENFERMEDADES NEURODEGENERATIVAS ENFERMEDAD DE PARKINSON ENSAYO CLINICO TRATAMIENTO MEDICO ATROFIA MULTISISTÉMICA Rascol, Olivier Cochen De Cock, Valérie Pavy-Le Traon, Anne Foubert Samier, Alexandra Thalamas, Claire Sommet, Agnès Rousseau, Vanessa Pérez Lloret, Santiago Fabbri, Margherita Azulay, Jean Philippe Corvol, Jean-Christophe Couratier, Philippe Damier, Philippe Defebvre, Luc Durif, Franck Geny, Christian Houeto, Jean-Luc Remy, Philippe Tranchant, Christine Verin, Marc Tison, François Meissner, Wassilios G. Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
description |
Abstract: Background: There are no effective treatments for multiple system atrophy (MSA).
Objective: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA.
Methods: This was a double-blind, parallel-group, placebo-controlled, randomized trial in patients with "probable" MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA-Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score.
Results: A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (-2.13 units [95% confidence interval, CI, -4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12-week in UMSARS Part II (exploratory outcome: -1.41 units [95% CI, -2.84; 0.03]; p = 0.05) and in MSA-QoL emotional/social dimension (secondary outcome: -6.99 units [95% CI, -13.40; -0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo).
Conclusion: The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation. |
format |
Artículo |
topic_facet |
NEUROBIOLOGIA ENFERMEDADES NEURODEGENERATIVAS ENFERMEDAD DE PARKINSON ENSAYO CLINICO TRATAMIENTO MEDICO ATROFIA MULTISISTÉMICA |
author |
Rascol, Olivier Cochen De Cock, Valérie Pavy-Le Traon, Anne Foubert Samier, Alexandra Thalamas, Claire Sommet, Agnès Rousseau, Vanessa Pérez Lloret, Santiago Fabbri, Margherita Azulay, Jean Philippe Corvol, Jean-Christophe Couratier, Philippe Damier, Philippe Defebvre, Luc Durif, Franck Geny, Christian Houeto, Jean-Luc Remy, Philippe Tranchant, Christine Verin, Marc Tison, François Meissner, Wassilios G. |
author_facet |
Rascol, Olivier Cochen De Cock, Valérie Pavy-Le Traon, Anne Foubert Samier, Alexandra Thalamas, Claire Sommet, Agnès Rousseau, Vanessa Pérez Lloret, Santiago Fabbri, Margherita Azulay, Jean Philippe Corvol, Jean-Christophe Couratier, Philippe Damier, Philippe Defebvre, Luc Durif, Franck Geny, Christian Houeto, Jean-Luc Remy, Philippe Tranchant, Christine Verin, Marc Tison, François Meissner, Wassilios G. |
author_sort |
Rascol, Olivier |
title |
Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
title_short |
Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
title_full |
Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
title_fullStr |
Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
title_full_unstemmed |
Fluoxetine for the symptomatic treatment of Multiple System Atrophy : the MSA-FLUO trial |
title_sort |
fluoxetine for the symptomatic treatment of multiple system atrophy : the msa-fluo trial |
publisher |
Wiley |
publishDate |
2021 |
url |
https://repositorio.uca.edu.ar/handle/123456789/11645 |
work_keys_str_mv |
AT rascololivier fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT cochendecockvalerie fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT pavyletraonanne fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT foubertsamieralexandra fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT thalamasclaire fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT sommetagnes fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT rousseauvanessa fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT perezlloretsantiago fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT fabbrimargherita fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT azulayjeanphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT corvoljeanchristophe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT couratierphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT damierphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT defebvreluc fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT duriffranck fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT genychristian fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT houetojeanluc fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT remyphilippe fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT tranchantchristine fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT verinmarc fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT tisonfrancois fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial AT meissnerwassiliosg fluoxetineforthesymptomatictreatmentofmultiplesystematrophythemsafluotrial |
_version_ |
1794795108229447680 |